title: Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
abstract: A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C. Pancreatic autoantibody tests were negative before the start of therapy, but a significant increase in glutamic acid decarboxylase (GAD) antibody titer was seen after 24 weeks of treatment. Six months after the onset of type 1 diabetes mellitus, the patient continues to receive 40 units of insulin daily. The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
authors.affiliation: Department of Gastroenterology, Mie University School of Medicine, Tsu.
authors.forename: Junichirou
authors.initials: J
authors.lastname: Tanaka
authors.forename: Kazushi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Katsuya
authors.initials: K
authors.lastname: Shiraki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Beppu
authors.forename: Kentarou
authors.initials: K
authors.lastname: Yoneda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fuke
authors.forename: Norihiko
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ito
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Takei
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005968:Glutamate Decarboxylase / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D005968:Glutamate Decarboxylase; C417083:peginterferon alfa-2b